Discover advanced Multiple Myeloma Treatment and Procedures at Liv Hospital. We offer stem cell transplants, immunotherapy, and personalized care pathways.
Send us all your questions or requests, and our expert team will assist you.
Treatment and Procedures
The landscape of Multiple Myeloma treatment has undergone a revolutionary transformation in the last decade. What was once considered a rapidly progressing disease is now manageable for many patients as a chronic condition, thanks to the introduction of novel agents, immunotherapies, and advanced stem cell transplantation techniques.
At Liv Hospital, our goal goes beyond just symptom management. We aim for “deep remission” , a state where no cancer cells can be detected in the body. By combining the latest FDA-approved drug protocols with our world-class bone marrow transplant infrastructure, we offer international patients access to the same high standards of care found in top US medical centers, often with faster accessibility.
This guide details the strategic phases of myeloma treatment, from the initial “induction” therapy to the life-saving potential of stem cell transplantation.
Treating multiple myeloma is rarely a one-step process. It typically follows a strategic timeline designed to reduce the tumor burden, eliminate residual cells, and maintain remission.
For most newly diagnosed patients, treatment begins with “Induction Therapy.” This usually involves a “triplet” or “quadruplet” regimen, a cocktail of three or four different types of drugs working together to attack the cancer from different angles.
Common agents used in these combinations include:
For eligible patients, an Autologous Stem Cell Transplant remains the “gold standard” of care in multiple myeloma treatment. It is not a surgery, but rather a complex procedure that allows doctors to use chemotherapy doses that are 5 to 10 times higher than normal.
Why is it necessary?
Myeloma cells are sensitive to chemotherapy, but so is healthy bone marrow. Standard doses of chemotherapy are limited by the damage they cause to your blood production. By collecting your stem cells before the high-dose chemotherapy, we can “rescue” your bone marrow afterward.
The Procedure at Liv Hospital:
For patients whose myeloma has relapsed (returned) or is refractory (stopped responding) to standard treatments, Liv Hospital offers access to cutting-edge immunotherapies.
CAR T-Cell Therapy: This is one of the most exciting advancements in cancer care. It involves taking the patient’s own T-cells (immune cells), genetically modifying them in a lab to recognize a specific protein on myeloma cells (BCMA), and infusing them back into the patient. These “supercharged” T-cells then hunt down and destroy the cancer.
Bispecific T-cell Engagers (BiTEs): These are “bridge” drugs that attach to both a cancer cell and a T-cell, pulling them together so the immune system can attack the cancer directly.
While drug therapies treat the whole body (systemic), local treatments are often needed to manage specific complications:
Send us all your questions or requests, and our expert team will assist you.
It is common for multiple myeloma to return eventually. This is called a relapse. When this happens, our team at Liv Hospital is prepared with “Second-Line” and “Third-Line” protocols.
Treating multiple myeloma requires more than just a doctor; it requires an ecosystem.
Like any major medical procedure, it carries risks, primarily related to infection while the immune system is recovering. However, autologous transplants (using your own cells) have a very low mortality rate (less than 1-2%) in experienced centers like Liv Hospital.
It depends on the drugs used. The high-dose chemotherapy (Melphalan) used during a stem cell transplant almost always causes hair loss. However, many modern induction therapies (like Revlimid or Velcade) do not typically cause significant hair loss.
Induction therapy typically lasts 3-4 months. If you proceed to a stem cell transplant, the hospital stay is usually 2-3 weeks, followed by a recovery period of 2-3 months at home or in a hotel near the hospital. Maintenance therapy can continue for years.
While “cure” is a difficult term in myeloma, “remission” is very achievable. With modern triplet therapies and transplantation, the median survival has more than tripled in recent years, with many patients living 10 years or more with good quality of life.
CAR T-Cell therapy is a highly specialized and regulated treatment. Availability depends on specific approvals and your eligibility. Our specialists can evaluate if you are a candidate for this or other advanced immunotherapies during your consultation.
Your Comparison List (you must select at least 2 packages)
